GlassScriptPhysician profile
Mhd N Rajeh
NPI 1528452240
$5,549.26
in general payments reported to CMS, 2019-2025
22 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $899 · 2020: $249 · 2021: $188 · 2022: $924 · 2023: $2,849 · 2024: $271 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,363 · Food and Beverage: $468 · Education: $439 · Travel and Lodging: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,362.50 |
| Food and Beverage | $468.37 |
| Education | $438.97 |
| Travel and Lodging | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,527.02 | 2023-2024 | |
| Astellas Pharma US INC | $581.98 | 2019-2023 | |
| Glaxosmithkline, LLC. | $430.00 | 2022 | |
| Janssen Biotech, INC. | $396.99 | 2019-2023 | Rybrevant |
| Amgen INC. | $294.40 | 2019-2022 | |
| Kite Pharma, INC. | $278.75 | 2019-2025 | Yescarta |
| Incyte Corporation | $238.38 | 2022-2024 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $158.93 | 2024 | Iclusig |
| Alexion Pharmaceuticals, INC. | $150.00 | 2020 | |
| Agios Pharmaceuticals, INC. | $128.99 | 2019 | |
| Genentech USA, INC. | $102.03 | 2019 | |
| Sanofi-Aventis U.S. LLC | $95.66 | 2022 | |
| Taiho Oncology, INC. | $40.00 | 2025 | |
| Merck Sharp & Dohme LLC | $29.63 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $23.05 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $21.85 | 2024 | |
| Fresenius Kabi USA, LLC | $19.02 | 2023 | Amicus Separator |
| Acrotech Biopharma INC. | $13.93 | 2022 | |
| Janssen Scientific Affairs, LLC | $11.97 | 2019 | |
| Pfizer INC. | $6.68 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mhd Rajeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.